Filing Flows › Generate Biomedicines (GENB) › Stock forecast & fair value
Generate Biomedicines (GENB) stock forecast and price target
Generate Biomedicines (GENB) trades at $13.06. 5 analysts' median price target is $27.00 (+107%), from $22.00 to $30.00.
Generate Biomedicines' latest quarter
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for GENB stock?
The median of 5 analysts' 12-month targets is $27.00, +107% from $13.06; the range is $22.00 to $30.00. The average rating is strong buy.
Does Generate Biomedicines usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is GENB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.